R&D BIO 2024 - Live Coverage pharmaphorum is back at the BIO International Convention this year, coming to you from sunny San Diego with two days of live coverage of one of the year’s biggest pharma executive gathering
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.